Navigation Links
YERVOY (ipilimumab) approved for the treatment of previously treated advanced melanoma in the EU
Date:7/14/2011

Paris, 14 July 2011 Bristol-Myers Squibb today announced that the European Commission has approved YERVOY (ipilimumab) for the treatment of adult patients with previously-treated advanced melanoma.

YERVOY, an innovative immunotherapy, showed long-term survival in the treatment of patients with advanced melanoma in a randomised, double-blind Phase III study published in the New England Journal of Medicine in June 2010.(1) Based on the survival (Kaplan-Meier) curve, the 1 and 2-year estimated survival rates for patients treated with YERVOY were 46% and 24% respectively vs. 25% and 14% in the comparator arm with some patients alive at 3 and 4 years.

"With the approval of YERVOY physicians now have an important new option to offer to patients with metastatic melanoma. This is a chance of not just months but potentially 3 to 4 years of prolonged survival for some patients in the treatment of metastatic melanoma," comments Professor Alexander Eggermont, General Director, Institut Gustave Roussy, Paris, France. "There is hope that YERVOY's novel mode of action, together with the fact that the recommended complete course of treatment with YERVOY (3 mg/kg) includes 4 infusions over 3 months, could potentially change the way we treat patients with previously treated advanced melanoma. It is an example of what can be done through unleashing the power of one's own immune response."

Bristol-Myers Squibb will now work closely with local health authorities to expedite the availability of YERVOY across the European Union. Prior to approval, the Company provided ipilimumab to nearly 3,000 patients throughout Europe through Compassionate Use / Named Patient Programmes. The Company remains committed to helping ensure that appropriate patients who need YERVOY will receive it while the reimbursement process is finalised by the relevant authorities throughout Europe.

Ron Cooper, President Bristol-Myers Squibb Europe, stated: "With an average survival time on diagnosis of 6-9 months, patients with advanced melanoma have had little hope - until now. The European Union approval of YERVOY is a milestone for patients with advanced disease and is the first outcome of Bristol-Myers Squibb's commitment to immuno-oncology. Through the Bristol-Myers Squibb String of Pearls strategy, we began a collaboration with Medarex, acquired the company and developed YERVOY. We will continue this strategy to seek and establish collaborations with other leading innovators across the globe. Through these and other initiatives we work towards our single mission: to discover, develop and deliver innovative medicines that help patients prevail over serious diseases."

YERVOY represents a new treatment paradigm in the evolving discipline of immuno-oncology. It indirectly targets the tumour by stimulating the patient's immune system to recognise and destroy cancer cells.(2) YERVOY specifically blocks cytotoxic T lymphocyte antigen 4 (CTL4), which plays a role in suppressing the normal immune response. YERVOY blocks that suppression to allow the immune system to respond to melanoma cancer cells.

The types of adverse events (AEs) attributed to YERVOY are generally mechanism (immune)-based. YERVOY can result in severe and fatal immune-related adverse reactions due to T-cell activation and proliferation. These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy. The majority of these immune-mediated reactions initially manifested during treatment; however, a minority occurred weeks to months after discontinuation of YERVOY. Patients should be assessed for signs and symptoms of enterocolitis, dermatitis, neuropathy and endocrinopathy and clinical chemistries should be evaluated, including liver function tests and thyroid function tests, at baseline and before each dose.

Adverse events associated with YERVOY are managed with protocol-specific guidelines, including the administration of systemic corticosteroids, dose interruption/discontinuation and/or other immunosuppressants.


'/>"/>

Contact: Elzbieta Zawislak
elzbieta.zawislak@bms.com
33-615-523-580
TogoRun
Source:Eurekalert

Related medicine news :

1. Rochester technology to enhance eyesight approved by FDA
2. FDA Bans Unapproved Prescription Cough, Cold and Allergy Meds
3. New drug for use in bone scans approved
4. Pradaxa Approved to Fight Dangerous Irregular Heartbeat, Stroke
5. First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial
6. The Good Nite Lite Awarded the Parent Tested Parent Approved Seal
7. U.S. FDA Adds 25 New Firms to Import Alert for Promotion of Unapproved New Drugs According to FDAImports.com, LLC
8. doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions
9. Parent Tested Parent Approved Media Announces their Winning Products for the Summer 2010 Campaign
10. Expert Approved: FatWallet Guides Mother's Day Shoppers to the Best Deals Online
11. Khanna Institute to Offer Newly FDA Approved Expanded Range of Intacs for Keratoconus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... 17, 2017 , ... The Alliance Healthcare Foundation (AHF) announced ... positively impact the health and wellness of our community in San Diego and ... to seriously consider releasing our assets beyond our 5% targeted distribution each year ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... brings its educational assistance management solution to the exhibit floor for the ... Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare industry ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Dr. Carol Francis' goals for each and every seminar, session and class ... will demonstrate five different brainwave tools which help energize creativity, focus mental functions, ...
(Date:2/17/2017)... WA (PRWEB) , ... February 17, 2017 , ... ... management organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum ... America's healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, ...
(Date:2/17/2017)... ... 17, 2017 , ... Program will serve more than 5,000 ... U.S. Soccer Foundation announced today that they have awarded nine grants to expand ... Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer while striving to ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... , Feb. 19, 2017  nThrive™, an ... cycle portfolio and thought leadership at the 2017 ... a category leader award from KLAS. ... discussion focused on how market trends shape the ... particularly a sophisticated, comprehensive Patient Access solution. The ...
(Date:2/18/2017)... , Feb. 17, 2017  Pharmaceutical companies have long ... products either in development or already on the market.   ... the pharma industry to alter how it manages advisory board ... leader Best Practices, LLC conducted a new study focused on ... ...
(Date:2/17/2017)... , Feb. 17, 2017 Theravance ... Biopharma" or the "Company") today announced the presentation ... potent, and orally administered pan-Janus kinase (JAK) inhibitor ... th Congress of the European Crohn,s and ... Company reported further data from its completed Phase ...
Breaking Medicine Technology: